Editor's note: SNMMI and the European Association of Nuclear Medicine periodically define
new standards/guidelines for nuclear medicine practice to help advance the science of …

In the past decade, the management of differentiated thyroid cancer (DTC) underwent a
paradigm shift toward the use of risk stratification with the goal of maximizing the benefit and …

Radiotheragnostics represents the systematic integration of diagnostic imaging and
therapeutics using radionuclides targeting specific characteristics of tumor biology …

During the last few years, especially since the American Thyroid Association guidelines was
released in 2015, there has been an intense debate on the management of thyroid cancer …

Abstract Objective According to the 2015 American Thyroid Association (ATA) guidelines,
thyroid ablation by iodine-131 (I-131) therapy is absolutely recommended only in patients …

Molecular imaging is pivotal in evaluating and managing patients with different thyroid
cancer histotypes. The existing, pathology-based, risk stratification systems can be usefully …

Aim Total thyroidectomy and risk-adapted 131-radioiodine therapy (RaIT) are the treatments
of choice in differentiated thyroid cancer (DTC) patients. The response to treatments is …

Background: The goal of radioactive iodine (RAI) in differentiated thyroid cancer (DTC) is to
treat metastasis and reduce recurrence risk. International guidelines provide broad risk …

Nuclear medicine is an essential tool in the delivery of high-quality medical care, going
beyond simple anatomic imaging to the use of physiologic processes for both imaging and …

Aim The risk of differentiated thyroid cancer (DTC) recurrence is widely evaluated according
to the 2015 ATA Risk Stratification System. Topography of malignant nodules has been …